In Japan, Fujifilm Vet Systems and Volition
Introduce the Nu.Q® Vet Cancer Test
March 20, 2024, HENDERSON, Nevada /PRNewswire/ -- The premier veterinary diagnostic laboratory service, Fujifilm Vet Systems Co. Ltd. ("Fujifilm Vet Systems"), and the multinational epigenetics business VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") have reached a supply agreement so that Volition can introduce the Nu.Q® Vet Cancer Test to Japanese veterinarians.
Thanks to a supply arrangement with Volition, Fujifilm Vet Systems can use the Nu.Q® Vet Cancer Test to test dogs for cancer across its network of central reference laboratories in Japan. An easily available and reasonably priced screening tool to help detect cancer in dogs early on is the Nu.Q® Vet Cancer Test.
Volition Veterinary Diagnostics Development LLC's CEO, Dr. Tom Butera, stated: "We are excited to be entering the Japanese market with Fujifilm Vet Systems. With a network of ten laboratories, it is the top veterinary diagnostic laboratory service in the nation, serving hospitals and veterinary clinics all throughout the nation.
"Japanese veterinarians will have access to a state-of-the-art test via Fujifilm Vet Systems that can aid in the early detection of cancer, improving patient care and outcomes. Our Nu.Q® Vet Cancer Test is a straightforward, user-friendly blood screening tool that may be used in conjunction with other standard bloodwork procedures during routine wellness visits and readily incorporated into preventive care programs."
The Chief Executive Officer of Singapore Volition, Dr. Jasmine Kway, further stated:
"Volition sees a large market opportunity in Japan as we work to grow our Nu.Q® Vet Cancer Test product throughout Asia. We are excited to collaborate with Fujifilm Vet Systems as they implement our test throughout its network of diagnostic laboratories across the nation."
"We are delighted to add the Nu.Q® Vet Cancer Test to our diagnostic service portfolio and expand our wellness testing offer to Japanese veterinarians," stated Kiyotaka Fujiwara, Chief Operating Officer of Fujifilm Vet Systems. As soon as the test becomes available for purchase, we will let our clients know."
Concerning Volition
The goal of the international epigenetics business Volition is to further the field of epigenetics. Through early detection and therapy monitoring, Volition is committed to saving lives and improving outcomes for individuals and animals with life-altering illnesses.
Through its subsidiaries, Volition is creating and distributing straightforward, user-friendly, reasonably priced blood tests to aid in the diagnosis and ongoing monitoring of a variety of illnesses, including some malignancies and conditions linked to NETosis, such sepsis. Patients' lives may be prolonged and their quality of life may be enhanced by early diagnosis and monitoring.
With offices and an innovation lab in the United States, as well as other locations in London and Singapore, Volition primarily conducts research and development in Belgium. Volition's supply arrangement with Fujifilm Vet Systems is with Belgian Volition SRL, a subsidiary of Volition.
This document does not include, nor should it be construed to include, any of the contents located at Volition's website URL. This document contains the website address just as an inactive textual reference.
Concerning FUJIFILM VR Systems
FUJIFILM VET Systems offers veterinary medical facilities around the country testing services focused on health examinations. Specialized examinations that are not possible at veterinary hospitals can also be handled by us. Furthermore, we have set up contract laboratories at ten locations throughout Japan, and we have led the industry in delivering services that use our testing and specimen collection networks to swiftly report test findings. Its promptness and convenience have been commended by veterinarians in veterinary clinics and hospitals across the country.
Safe Harbor Announcement
Articles in this press release that address matters involving risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements may be considered "forward-looking statements" under Sections 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933, as amended. Statements that are forward-looking are identified by terms like "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will," and similar forms. These predictions include information about Volition's estimated market opportunity, the efficacy of its blood-based diagnostic, prognostic, and disease monitoring tests, and the company's capacity to create and effectively market test platforms for the early detection Due to a number of risks and uncertainties, including without limitation the findings of studies examining the effectiveness of Volition's tests, the company's actual results could differ significantly from those projected in these forward-looking statements. For example, Volition may not be able to carry out its operational plan if it is unable to create and commercialize diagnostic, prognostic, or disease monitoring products. Volition faces several risks and uncertainties, such as the inability to obtain regulatory clearances or approvals required for the distribution and marketing of future products; the market's rejection of products in Volition's development pipeline or any other products Volition may develop related to diagnosis, prognosis, or disease monitoring; the inability to secure sufficient intellectual property protection; intense competition; and the possibility that Volition's intended products will become outdated due to the highly competitive These predictions, forecasts, and expectations concerning Volition's business are based in part on management-made assumptions. These claims contain difficult-to-predict risks, uncertainties, and assumptions, and they do not guarantee future performance. This release contains forward-looking statements as of the date of its release. Volition does not assume any obligation to update these statements to reflect events or circumstances in the future, unless mandated by law.
VolitionRx Limited and its subsidiaries own the trademarks and/or service marks NucleosomicsTM, Nu.Q®, and their corresponding logos. The proprietors of all other trade names, trademarks, and service marks mentioned in this press release are the rightful owners.
0 Comments